LCTX Lineage Cell Therapeutics, Inc.

1.39
-0.06  -4%
Previous Close 1.45
Open 1.38
Price To Book 4.63
Market Cap 624,642,342
Shares 449,382,980
Volume 585,274
Short Ratio 7.07
Av. Daily Volume 1,113,490
Stock charts supplied by TradingView

NewsSee all news

  1. Lineage Cell Therapeutics to Present at Biocom's 10th Annual Global Life Sciences Partnering Conference

    Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that Brian M. Culley, Chief Executive

  2. Lineage Cell Therapeutics to Present New Data From OpRegen® and Vision Restoration Programs at the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2020)

    Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that updated results from a Phase I/IIa

  3. Lineage Cell Therapeutics to Present at NobleCon16 - Noble Capital Markets' Sixteenth Annual Investor Conference

    Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that Brian M. Culley, Chief Executive

  4. Lineage Provides Positive Update on Phase I/IIa Clinical Study of OpRegen® for the Treatment of Dry Age-Related Macular Degeneration

    Removal of Enrollment Stagger and Opening of Leading Ophthalmology Clinical Sites at Cincinnati Eye Institute and Wills Eye Hospital Expected to Significantly Accelerate Patient Enrollment Lineage Cell Therapeutics,

  5. Lineage Cell Therapeutics Conducts Sale of Shares in OncoCyte Corporation

    Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced the pricing of the sale of 2,383,090 shares of

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1 immunogenicity data due 1Q 2020.
VAC2
Non-small cell lung cancer (NSCLC)
Phase 1/2 updates due throughout 2020.
AST-OPC1 SCiSTAR
Cervical spinal cord injury
Phase 1/2 enrolment to be completed 1Q 2020. Data due at ARVO May 3-7, 2020.
OpRegen
Dry age-related macular degeneration (AMD)

Latest News

  1. Lineage Cell Therapeutics to Present at Biocom's 10th Annual Global Life Sciences Partnering Conference

    Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that Brian M. Culley, Chief Executive

  2. Lineage Cell Therapeutics to Present New Data From OpRegen® and Vision Restoration Programs at the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2020)

    Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that updated results from a Phase I/IIa

  3. Lineage Cell Therapeutics to Present at NobleCon16 - Noble Capital Markets' Sixteenth Annual Investor Conference

    Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that Brian M. Culley, Chief Executive

  4. Lineage Provides Positive Update on Phase I/IIa Clinical Study of OpRegen® for the Treatment of Dry Age-Related Macular Degeneration

    Removal of Enrollment Stagger and Opening of Leading Ophthalmology Clinical Sites at Cincinnati Eye Institute and Wills Eye Hospital Expected to Significantly Accelerate Patient Enrollment Lineage Cell Therapeutics,

  5. Lineage Cell Therapeutics Conducts Sale of Shares in OncoCyte Corporation

    Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced the pricing of the sale of 2,383,090 shares of

  6. Lineage Provides Update on Patient Enrollment in Phase I/IIa Clinical Study of OpRegen® for the Treatment of Dry Age-Related Macular Degeneration

    Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cellular therapies for unmet medical needs, today announced additional patient data from its

  7. Lineage Cell Therapeutics Enters Into Three Separate License Agreements for Certain Intellectual Property and Assets

    Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cellular therapies for unmet medical needs, today announced that it has entered into license

  8. Lineage Cell Therapeutics Provides Shareholder Update

    Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cellular therapies for unmet medical needs, today provided a year-end review and an outline of

  9. Lineage Cell Therapeutics and AgeX Therapeutics Announce Issuance of U.S. Patent for Method of Generating Induced Pluripotent Stem Cells

    Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX) and AgeX Therapeutics, Inc. (NYSE:AGE), announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 10,501,723,

  10. AgeX Therapeutics and Lineage Cell Therapeutics Announce Issuance of U.S. Patent for Method of Generating Induced Pluripotent Stem Cells

    AgeX Therapeutics, Inc. (NYSE:AGE) and Lineage Cell Therapeutics, Inc. (NYSE American and TASE LCTX), announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 10,501,723,

  11. Lineage Cell Therapeutics Provides Update on SCiStar Clinical Study and OPC1 Spinal Cord Injury Program

    OPC1 Overall Safety Profile Excellent with Motor Recovery Gains in Upper Extremities Maintained Through Year 2 Follow-Ups Available to Date OPC1 Manufacturing Fully Transferred to cGMP Facility; Improvements to

  12. Lineage Cell Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update

    New Data from Phase I/IIa Clinical Study of OpRegen® Presented at 2019 AAO Meeting; All Cohort 4 Patients Have Better Visual Acuity as of Last Visit Implemented Significant Additional Cost-Cutting Measures to Reduce

  13. Lineage Cell Therapeutics to Report Third Quarter 2019 Financial Results and Provide Business Update on November 12, 2019

    Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that it will report its third quarter 2019

  14. Lineage Cell Therapeutics to Present at Dawson James Securities 5th Annual Small Cap Growth Conference on October 29, 2019

    Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that Brandi L. Roberts, Chief Financial

  15. Lineage Cell Therapeutics Presents New OpRegen® Data at American Academy of Ophthalmology Annual Meeting

    Treatment with OpRegen Continues to be Well Tolerated with Increased Visual Acuity Observed in Cohort 4 Patients Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company

  16. Lineage Cell Therapeutics to Chair Session and Present Data on Vision Restoration Program at Society for Neuroscience's 49th Annual Scientific Meeting on October 23, 2019

    Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that Igor Nasonkin, Ph.D., Principal

  17. Lineage Cell Therapeutics to Present New OpRegen® Data at American Academy of Ophthalmology Annual Meeting on October 14, 2019

    Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that updated results from a Phase I/IIa

  18. Lineage Cell Therapeutics to Present at 2019 Cantor Global Healthcare Conference on October 4, 2019

    Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that Brandi L. Roberts, Chief Financial

  19. Lineage Cell Therapeutics Provides Update on Renevia® Commercialization Plans

    Sercader Ltd. Engaged to Identify European Commercial Partner Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical

  20. Lineage Cell Therapeutics to Present at 2019 Cell & Gene Meeting on the Mesa on October 3, 2019

    Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that Brian M. Culley, Chief Executive

  21. Lineage Cell Therapeutics Receives CE Mark Approval for Renevia®

    Comparative clinical trial met its primary endpoint of change in hemifacial volume at six months (p<.001) Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company

  22. Lineage Cell Therapeutics Conducts Sale of Shares in OncoCyte Corporation

    Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced the pricing of the sale of 4,000,000 shares of